BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScapeâ"¢, a multiomics research initiative designed by CareDx to eluci. ...

In the second quarter, 10x Genomics ( TXG ) swung to a surprise profitability. Many were very encouraged by this, and I upgraded them from a sell to a hold , saying that while itI’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsible Statecraft. I have been writing inves ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Core Insights - The company reported solid business fundamentals despite a challenging funding environment, with key positive drivers of performance continuing into Q2 [1][2] - Total revenue for Q2 was $173 million, with a notable settlement payment of $68 million from patent litigation contributing to the financial results [4][21] - The company is focused on advancing technology leadership in single-cell and spatial biology, with new product launches expected to enhance capabilities and drive growth [10][12] Financial Performance - Total revenue for Q2 was $172.9 million, representing a 13% increase year-over-year, while excluding the settlement revenue, it was $145.6 million, down 5% [21] - Consumables revenue was $122.2 million, down 1%, with spatial consumables revenue increasing by 24% to $36.4 million, driven by Xenium products [21] - Operating income for Q2 was $30.1 million compared to an operating loss of $41.7 million in the previous year, indicating a significant turnaround [24][25] Market Dynamics - The funding environment remains uncertain, particularly in the academic sector, leading to cautious customer spending and extended project timelines [2][7] - Despite these challenges, there is a strong demand for single-cell and spatial biology tools, with researchers increasingly investing in these technologies [8][9] - The company noted a temporary increase in purchasing activity in China, driven by customers accelerating orders ahead of potential tariff changes, estimating a $4 million revenue impact from this pull forward [23][51] Product Development and Innovation - The company launched several new products, including Visium HD 3 Prime and Flex v2, aimed at increasing throughput and lowering costs for researchers [10][11] - The acquisition of Scale Biosciences is expected to enhance the company's capabilities in single-cell analysis, making it more powerful and accessible [16][17][18] - The company is prioritizing the integration of new technologies to support larger-scale applications and maintain high-quality data standards [17][18] Customer Engagement and Sentiment - The company is closely monitoring customer sentiment and remains aligned with them to navigate the uncertain funding landscape [2][7] - Conversations with customers indicate that clarity on future budgets and the actual disbursement of funds are critical for unlocking spending [8][64] - The company is optimistic about the long-term potential of its products, as customer feedback remains positive regarding the quality and utility of its offerings [6][48]

Upgrades - Baird upgraded Albemarle (ALB) to Neutral from Underperform with a price target of $113, up from $81, due to optimism regarding lithium end-market demand tied to energy storage [2] - Morgan Stanley upgraded DexCom (DXCM) to Overweight from Equal Weight with a price target of $75, up from $63, citing signs of recovery from operational challenges while valuation remains at trough levels [2] - Argus upgraded Restaurant Brands (QSR) to Buy from Hold with an $85 price target, expecting strong brands to lead to higher domestic comparable sales and international unit expansion [3] - Truist upgraded Six Flags (FUN) to Buy from Hold with a price target of $23, down from $27, noting the new CEO's promising approach to improve underperforming parks [3] - Stifel upgraded Teradyne (TER) to Buy from Hold with a price target of $225, up from $162, anticipating accelerated growth due to a favorable shift in test revenue composition [4] Downgrades - Morgan Stanley downgraded Inspire Medical (INSP) to Equal Weight from Overweight with a price target of $130, up from $105, citing lack of visibility into the core business and long-term market potential [5] - Goldman Sachs downgraded Symbotic (SYM) to Sell from Neutral with an unchanged $47 price target, believing the valuation is stretched with a 185-times enterprise value to expected forward adjusted EBITDA multiple [5] - Oppenheimer downgraded Sound Point Meridian Capital (SPMC) to Perform from Outperform, removing the price target of $20, due to higher than expected negative impact on earnings from borrower call options [5] - Morgan Stanley downgraded 10x Genomics (TXG) to Equal Weight from Overweight with a price target of $20, up from $17, following a stock rally that placed the multiple in a reasonable spot relative to growth [5] - BofA downgraded PagerDuty (PD) to Underperform from No Rating with a $12 price target, citing demand headwinds and a pricing model change that may delay growth stabilization [5]

Core Insights - Torex Gold Resources Inc. reported promising drill results from the 2025 drilling program at Media Luna West, supporting the declaration of an inaugural Inferred Resource in March 2026 [1][2][15] Drilling Results - The drilling program defined a mineralized footprint of 400 x 300 meters, with high-grade results including 12.25 grams per tonne gold equivalent (gpt AuEq) over 11.0 meters in drill hole ML25-1088D and 17.79 gpt AuEq over 12.9 meters in ML25-1095D [2][14] - A total of 10,744 meters of drilling was conducted across 23 drill holes in 2025, with an additional drill hole from 2024, totaling 11,303 meters over 24 drill holes [7][16] Future Plans - Future drilling will focus on expanding the resource footprint towards the north and south, particularly towards the San Miguel fault, and upgrading resources from Inferred to Indicated category [2][15] - The company anticipates sharing results from other targets across the Media Luna Cluster and Atzcala in the coming months, showcasing the exploration potential at Morelos [4][5] Geological Insights - The exploration at Media Luna West is guided by a deeper understanding of structural controls, focusing on the intersection of north-south structural corridors with west-northwest-striking faults linked to the San Miguel fault [6][19] - The mineralization is characterized by a sequence that began with copper-rich mineralization, followed by gold-rich fluids that preferentially mineralized the fringes of breccias [13][22] Strategic Objectives - Torex aims to enhance and extend the production profile of the Morelos Complex by expanding resources and increasing reserves, with a target of sustaining production above 450,000 gold equivalent ounces well beyond 2030 [4][29] - The company is committed to responsible mining and seeks to optimize production and costs while pursuing disciplined growth and capital allocation [30][28]

Summary of 10X Genomics Conference Call Company Overview - **Company**: 10X Genomics (NasdaqGS:TXG) - **Industry**: Biotechnology, specifically focusing on single-cell analysis and spatial omics Key Points and Arguments Company Position and Strategy - 10X Genomics is recognized as a market leader in single-cell analysis and spatial omics, with a strong emphasis on innovation and continuous improvement [1][2] - The company underwent significant restructuring in the past year, which has positioned it well to navigate a challenging macro environment [6][7] - The executive team changes and commercial restructuring have allowed for better responsiveness to market conditions [15][16] Market Environment - The current market environment is described as "choppy and uncertain," but there are signs of improvement in customer sentiment compared to earlier in the year [12][13] - Funding uncertainties, particularly related to NIH funding and multi-year funding, continue to pose challenges [11][12] Commercial Performance - The new commercial organization is performing well, with strong metrics in funnel management and opportunity generation despite macroeconomic challenges [18][19] - The company has seen growth in Chromium reaction and spatial consumables, indicating positive underlying business fundamentals [8][9] Pricing Strategy - 10X Genomics is actively working on pricing strategies to drive volume, particularly in single-cell consumables, by introducing lower price points and new product configurations [22][23] - The company anticipates that pricing pressures will normalize over the next few quarters, allowing for a better balance between pricing and volume [25][26] Competitive Landscape - The competitive landscape remains intense, but 10X Genomics believes it has maintained an advantage in product performance, quality, and customer satisfaction [44][45] - The company is sequencer agnostic, which enhances its competitive position as new sequencers enter the market [47][49] Future Opportunities - There is a growing interest in large-scale single-cell programs, particularly with the integration of AI in biological modeling, which could drive demand for 10X Genomics' products [30][32] - The company is open to partnerships with tech firms to leverage AI and enhance data analysis capabilities [37][38] Spatial Omics - Spatial technology is still in an earlier stage of development compared to single-cell technology, but it is expected to become increasingly important as the company improves its offerings [39][40] Financial Guidance - The company is cautious about providing financial guidance due to ongoing uncertainties in the market, but it remains optimistic about the underlying drivers of the business [54][59] Additional Important Insights - The company has made significant strides in product launches, including the recent introduction of the Flex assay, which is expected to enhance market performance [50][51] - There is a belief that substantial public investment in large-scale biological modeling could yield significant benefits for the industry [35][36]

Core Insights - 10x Genomics has launched its next-generation Chromium Flex assay, which significantly enhances the capacity for single-cell experiments by supporting up to 384 samples and processing as many as 100 million cells per week [1][2]. Group 1: Product Launch and Features - The new Chromium Flex assay is designed for high cell-number applications like CRISPR screens and high sample-number applications such as FFPE-based translational research [2]. - This release allows laboratories to achieve throughput levels previously only possible with bulk methods while maintaining single-cell resolution, marking a "transformational step forward" for foundational and translational research according to CTO Michael Schnall-Levin [2]. Group 2: Market Target and Applications - The Chromium Flex assay is now globally available and targets academic, biotech, and pharmaceutical labs that require automated, high-throughput solutions for precision cell profiling [3]. - 10x Genomics specializes in life sciences tools, developing platforms for single-cell and spatial biology, enabling high-resolution molecular analysis across various research domains including oncology, immunology, and neuroscience [3].

Core Insights - 10x Genomics, Inc. will participate in a fireside chat at the Wolfe Research Healthcare Conference 2025 on November 18, 2025, at 11:20 a.m. Eastern Time [1] - Interested parties can access a live webcast of the event on the company's website, which will be archived for at least 30 days [2] Company Overview - 10x Genomics is a life science technology company focused on products that enhance the understanding of biology and improve human health [3] - The company offers integrated research solutions, including instruments, consumables, and software for single cell and spatial biology, aiding researchers in comprehending biological systems [3] - Its products contribute to advancements in various fields such as oncology, immunology, and neuroscience, leading to significant discoveries in health and disease [3]

Core Insights - 10x Genomics reported third-quarter financial results that exceeded Wall Street expectations, leading to a 14.3% increase in share price [1][2] - The company projected fourth-quarter revenue between $154 million and $158 million, surpassing analysts' forecasts, indicating strong confidence in future performance [2] Financial Performance - For Q3, 10x Genomics generated revenue of $149 million, above the consensus estimate of $142.4 million [2] - The loss per share was $0.22, which was narrower than the anticipated loss of $0.28 [2] - The stock closed at $15.25, reflecting a 17.4% increase from the previous close [3] Market Reaction - The shares of 10x Genomics have shown extreme volatility, with 48 moves greater than 5% in the past year, indicating significant market impact from recent news [4] - The previous notable stock movement occurred 18 days prior, when the stock rose 6% after BofA Securities maintained a "Buy" rating while lowering the price target from $15.00 to $13.00 [5] Investment Performance - Year-to-date, 10x Genomics shares are up 7.5%, trading close to a 52-week high of $16.47 [6] - An investment of $1,000 in 10x Genomics shares five years ago would now be valued at $113.74 [6]